Metformin 1,700 mg/day and Dapagliflozin 10 mg/day for a year.

PreDiabetes

Obesity, Morbid

Diabetes Mellitus, Type 2

Two tablets of Metformin 850 mg every 12 hours will be provided in combination with Dapagliflozin 10 mg per day. Each participant will receive diet and exercise intervention according to their BMI and current physical condition.

Dapagliflozin/Metformin

Two tablets of Metformin 850 mg every 12 hours will be provided. Each participant will receive diet and exercise intervention according to their BMI and current physical condition.

Metformin

Hospital de Especialidades Centro Médico Nacional Siglo XXI

Effectiveness of Dapagliflozin for Weight Loss

Effectiveness of the Treatment With Dapagliflozin and Metformin Compared to Metformin Monotherapy for Weight Loss on Diabetic and Prediabetic Patients With Obesity Class III

Change of 10 percent of initial blood pressure (systolic and diastolic)

Change of 10 percent of initial waist circumference

Change of 10 percent of initial triglycerides levels

Change in interleukin-6, interleukin-10, adiponectin, and resistin, comparing initial versus final levels

Aldo Ferreira Hermosillo

Research Associate

Centro Medico Nacional Siglo XXI IMSS

Randomized single-blind controlled clinical trial

varenicline 1 mg BID. The duration of active treatment will be 12 weeks.

Smoking Cessation

Diabetes

varenicline at a dose of 1 mg twice a day for 12 week

varenicline

placebo at a dose of 1 mg twice for 12 week

placebo tablet is made of lactose

Centro per la Prevenzione e Cura del Tabagimso

Centro per la Prevenzione eCura del Tabagimso

Efficacy And Safety Of Smoking Cessation With Varenicline Tartrate In Diabetic Smokers: (DIASMOKE)

Efficacy And Safety Of Smoking Cessation With Varenicline Tartrate In Diabetic Smokers: A Double-Blind, Placebo-Controlled, Randomized, Trial

Adverse events observed or reported will be recorded. Assessments as to seriousness, severity, and the relationship to treatment and other causes will be made. Physical examination will be performed at the screening visit and at Wk 12. Blood pressure and heart rate will be measured at all visits. BMI and waist will be calculated at the screening visit and at Week 13, 24, 52. Blood chemistry, complete blood count, and urinalysis will be completed at screening, baseline, Week 2 and 12.

Subjects will be classified as responders if they are able to maintain abstinence from cigarette smoking during this period of time with end-expiratory exhaled CO measurements ≤ 10 ppm. This measure will be obtained through reports of cigarette use by means of the Nicotine Use Inventory (NUI) during the last three study visits (week 24, week 36 and week 44) confirmed by a measurement of an end-expiratory exhaled carbon monoxide concentration that is ≤ 10 ppm on each study visit.

Express the percentage of participants with Adverse Events in the active and in the placebo group.

This measures the % change from baseline. An improvement in systolic blood pressure is anticipated.

This measures the % change from baseline. An improvement in HbA1c is anticipated

This measures the % change from baseline. An slight increase in BMI is expected in the first few months after cessation.

Riccardo Polosa

Professor of Internal Medicine

Universita degli Studi di Catania

All patients receiving 6 weeks Rifaximin 400mg twice daily, followed by a 6 week observation period.

Patients Combined

Sex: Female, Male

Change in Alanine aminotransferase (ALT) from baseline

Rifaximin: Rifaximin tablet, oral administration, 400mg twice daily for 6 weeks.

Rifaximin

Follow-up after 6 weeks of treatment of Rifaximin

Standard of Care

Change in Serum Alanine Aminotransferase (ALT) Levels

Hepatic and systemic insulin resistance assessed using the hyperinsulinaemic euglycaemic clamp method.
Measured in % Suppression of Endogenous Glucose Production (SEGP).

Change in Insulin Resistance

In vivo proton magnetic resonance spectroscopy (1H MRS) to derive a T2-corrected triglyceride to water ratio (hepatic lipid content- intra-hepatocellular lipid (IHCL))

Follow-up after 6 weeks of treatment Rifaximin

Change in Hepatic Triglyceride Content

Rifaximin for 6 weeks in addition to standard care, followed by 6 weeks observation period during which patients receive standard care.
Rifaximin: Rifaximin tablet, oral administration, 400mg twice daily for 6 weeks.

Rifaximin for 6-weeks Then Standard Care

Overall Study

Dr Jeremy Cobbold

Participants received rifaximin tablet, oral administration, 400mg twice

Standard Care

Nonalcoholic Fatty Liver Disease

NAFLD

Nonalcoholic Steatohepatitis

Rifaximin tablet, oral administration, 400mg twice daily for 6 weeks.

Liver Unit, St Mary's Hospital, Imperial College London

Rifaximin in Fatty Liver Disease

RiFL: Rifaximin in Fatty Liver Disease. Does Modulation of Gut Microbiota Reduce Hepatic Inflammation in Non-Alcoholic Steatohepatitis (NASH)?

Imperial College London

National Health Service, United Kingdom

An open label pilot study with two phases (rather than 2 arms). All patients receiving 6 weeks Rifaximin 400mg twice daily, followed by a 6 week observation period.

blister/triglyceride

Effectiveness of Dapagliflozin for Weight Loss

Efficacy And Safety Of Smoking Cessation With Varenicline Tartrate In Diabetic Smokers: (DIASMOKE)

Rifaximin in Fatty Liver Disease

Täydellisin lääketieteellinen tietokanta tieteen tukemana